Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells

Acta Pharm Sin B. 2022 Jun;12(6):2905-2922. doi: 10.1016/j.apsb.2022.02.029. Epub 2022 Mar 4.

Abstract

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. Guided by X-ray crystallography and structure-based optimization, we report a novel subseries of C-3-substituted 6-ethynyl-1H-indole derivatives that display high potential and specificity towards group II PAKs. Among these inhibitors, compound 55 exhibited excellent inhibitory activity and kinase selectivity, displayed superior anti-migratory and anti-invasive properties against the lung cancer cell line A549 and the melanoma cell line B16. Compound 55 exhibited potent in vivo antitumor metastatic efficacy, with over 80% and 90% inhibition of lung metastasis in A549 or B16-BL6 lung metastasis models, respectively. Further mechanistic studies demonstrated that compound 55 mitigated TGF-β1-induced epithelial-mesenchymal transition (EMT).

Keywords: Anti-cancer; Cocrystallization; EMT; Kinase selectivity; Lung metastasis; PAK4 inhibitor.